At a glance
- Originator Aventis
- Class Antineoplastics; Small molecules
- Mechanism of Action Farnesyltranstransferase inhibitors; Ras protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 29 Apr 2013 added ras MoA
- 23 Dec 1999 Rhône-Poulenc Rorer has merged with Hoechst Marion Roussel to form Aventis Pharma
- 12 Jun 1997 Preclinical development for Cancer in France (Unknown route)